Oramed Pharmaceuticals (ORMP) News Today → On June 10, Nvidia makes its next big move (From Weiss Ratings) (Ad) Free ORMP Stock Alerts $2.18 -0.06 (-2.68%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 8:08 AM | americanbankingnews.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Forecasted to Earn Q2 2024 Earnings of $0.04 Per ShareMay 31 at 3:21 AM | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below 200 Day Moving Average of $2.53Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below 200-Day Moving Average of $2.53May 29 at 6:20 PM | finance.yahoo.comORMP: Moving Oral Delivery Platform Forward, + Potential to Generate RoyaltiesMay 23, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. Cut by Analyst (NASDAQ:ORMP)May 22, 2024 | marketbeat.comHC Wainwright Weighs in on Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Analysts at HC Wainwright cut their Q3 2024 EPS estimates for shares of Oramed Pharmaceuticals in a research report issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earniMay 22, 2024 | americanbankingnews.comResearch Analysts Issue Forecasts for Oramed Pharmaceuticals Inc.'s Q1 2025 Earnings (NASDAQ:ORMP)May 21, 2024 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Forecasted to Earn Q1 2025 Earnings of ($0.07) Per ShareOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - HC Wainwright issued their Q1 2025 earnings per share estimates for Oramed Pharmaceuticals in a report released on Monday, May 20th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will post earnings per shareMay 20, 2024 | marketbeat.comHC Wainwright Reaffirms "Neutral" Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)HC Wainwright reissued a "neutral" rating on shares of Oramed Pharmaceuticals in a research report on Monday.May 12, 2024 | finance.yahoo.comOramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)May 10, 2024 | investorplace.comORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024April 27, 2024 | marketbeat.comShort Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Declines By 37.0%Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 367,600 shares, a decrease of 37.0% from the March 31st total of 583,900 shares. Based on an average daily volume of 168,800 shares, the days-to-cover ratio is currently 2.2 days.April 24, 2024 | marketbeat.comBML Capital Management LLC Has $2.91 Million Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)BML Capital Management LLC increased its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 61.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,261,559 shares of the biotecApril 15, 2024 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Growth in Short InterestOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 583,900 shares, an increase of 20.6% from the March 15th total of 484,000 shares. Based on an average trading volume of 174,600 shares, the short-interest ratio is currently 3.3 days.March 16, 2024 | finance.yahoo.comORMP Apr 2024 2.500 putMarch 9, 2024 | finance.yahoo.comOramed Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsMarch 6, 2024 | marketbeat.comTrading was temporarily halted for "ORMP" at 09:03 AM with a stated reason of "LULD pause." Trading set to resume at 09:03 AM. February 22, 2024 | marketbeat.comRathbones Group PLC Acquires Shares of 289,803 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Rathbones Group PLC bought a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 289,803 shares of the biotechnology company's stock, valuedFebruary 21, 2024 | msn.comOramed to reinitiate pivotal type 2 diabetes trial after Phase III flopFebruary 20, 2024 | finanznachrichten.deOramed Pharmaceuticals Inc.: Oramed Letter to ShareholdersFebruary 20, 2024 | prnewswire.comOramed Letter to ShareholdersJanuary 24, 2024 | finance.yahoo.comORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery PlatformNovember 28, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39November 2, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21October 6, 2023 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year agoSeptember 21, 2023 | finance.yahoo.comOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanySeptember 8, 2023 | marketbeat.comCorsair Capital Management L.P. Makes New Investment in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Corsair Capital Management L.P. purchased a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 47,256 shares of the biotechnologyAugust 2, 2023 | finance.yahoo.comOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyJuly 28, 2023 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Down 15.1% in JulyOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 677,000 shares, a decrease of 15.1% from the June 30th total of 797,800 shares. Based on an average trading volume of 869,200 shares, the days-to-cover ratio is presently 0.8 days.July 25, 2023 | jp.reuters.comOramed Pharmaceuticals, Inc.July 3, 2023 | marketbeat.comETF Managers Group LLC Acquires Shares of 68,940 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)ETF Managers Group LLC acquired a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 68,940 shares of the biotechnology company's stock, valued at apprJune 20, 2023 | finance.yahoo.comOramed to Present at the 83rd American Diabetes Association ConferenceJune 17, 2023 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth PlansJune 2, 2023 | marketbeat.comCitigroup Inc. Has $793,000 Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Citigroup Inc. grew its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Rating) by 115.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,890 shares of the biotechnMay 30, 2023 | finance.yahoo.comORMP: Advancing Development Efforts in ChinaMay 28, 2023 | marketbeat.comRussell Investments Group Ltd. Makes New $680,000 Investment in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Russell Investments Group Ltd. purchased a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Rating) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 56,516 shares of the biotechMay 26, 2023 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) to Post Q2 2023 Earnings of ($0.09) Per Share, HC Wainwright ForecastsOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Rating) - Equities researchers at HC Wainwright increased their Q2 2023 earnings estimates for shares of Oramed Pharmaceuticals in a research note issued on Wednesday, May 24th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnologMay 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Oramed Pharm (ORMP)May 18, 2023 | msn.comCanaccord Genuity Maintains Oramed Pharmaceuticals (ORMP) Hold RecommendationMay 18, 2023 | finance.yahoo.comOramed to Present at Novel Therapies for Type 2 Diabetes & Obesity SummitMay 18, 2023 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Receives New Coverage from Analysts at StockNews.comStockNews.com initiated coverage on shares of Oramed Pharmaceuticals in a research report on Thursday. They issued a "hold" rating on the stock.May 16, 2023 | msn.comOramed Surges on New Diabetes TreatmentMay 15, 2023 | msn.comWhy Oramed Pharmaceuticals Shares Are Trading Higher TodayMay 15, 2023 | finance.yahoo.comOramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in ChinaMay 11, 2023 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Down 33.4% in AprilOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Rating) saw a large drop in short interest in April. As of April 30th, there was short interest totalling 520,400 shares, a drop of 33.4% from the April 15th total of 781,200 shares. Based on an average daily volume of 720,700 shares, the days-to-cover ratio is presently 0.7 days.May 3, 2023 | msn.comInvesting millions, Ben Shapiro joins board of Oramed PharmaceuticalsMay 2, 2023 | marketwatch.com8-K: ORAMED PHARMACEUTICALS INC.May 2, 2023 | finance.yahoo.comConservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug CompanyMay 1, 2023 | finance.yahoo.comOramed Appoints Ben Shapiro to its Board of DirectorsApril 5, 2023 | money.usnews.comOramed Pharmaceuticals, IncMarch 27, 2023 | finance.yahoo.comThe past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Don’t buy a single NVIDIA share before you see this... (Ad)If you feel like NVIDIA is still a good buy - be careful. Billionaires like Steve Cohen, Stanley Druckenmiller and George Soros are ALL dumping NVIDIA... And piling into an overlooked sector... I've prepared a short briefing with all the proof ORMP Media Mentions By Week ORMP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORMP News Sentiment▼1.090.78▲Average Medical News Sentiment ORMP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORMP Articles This Week▼60▲ORMP Articles Average Week Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FibroBiologics News Today Verrica Pharmaceuticals News Today Shattuck Labs News Today AC Immune News Today Organogenesis News Today Amarin News Today Alto Neuroscience News Today Precigen News Today Skye Bioscience News Today Nkarta News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORMP) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace“Financial tsunami is coming to America”Porter & CompanyNvidia is about to pass AppleWeiss RatingsUnlock Explosive Gains with This Defense StockBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
